NCCN Grants UNLOXCYT Category 2A Preferred Status in Advanced Skin Cancer
NCCN lists Sun Pharma's UNLOXCYT as a Category 2A preferred option in advanced skin cancer, strengthening payer coverage and prescribing confidence.
Topic
Nccn Guidelines
Topic